<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00522353</url>
  </required_header>
  <id_info>
    <org_study_id>UC 20085</org_study_id>
    <nct_id>NCT00522353</nct_id>
  </id_info>
  <brief_title>Prebiotic Fiber as a Modifier of Satiety Hormones and Body Weight in Overweight and Obese Adults</brief_title>
  <official_title>Effect of Oligofructose Versus Placebo on Body Weight and Satiety Hormone Secretion in Overweight and Obese Adults.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if oligofructose supplementation promotes weight
      loss in overweight and obese adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obesity is a primary health concern for many western countries as it is linked to several
      chronic diseases as well as, large health care costs. Although obesity is a multifactorial
      disease, it is known that levels of satiety hormones including glucagon like peptide-1
      (GLP-1) and peptide YY (PYY) are reduced in obesity. The ability of prebiotic fiber to
      promote weight loss through the production of satiety hormones has been tested previously
      using rodents. Here it was found that prebiotic supplementation resulted in a decreased
      energy intake, higher GLP-1 levels in the plasma and increased proglucagon mRNA levels in the
      gut. This study will address the important question of whether prebiotic fiber
      supplementation is effective in reducing body weight in overweight or obese human subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body weight</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma satiety hormones</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oligofructose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oligofructose</intervention_name>
    <description>21 grams per day in distributed over 3 doses per day for 3 months</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Raftilose P95</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>7.89 grams of placebo maltodextrin divided into 3 equal doses per day for 3 months</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Maltrin M100</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  overweight or class I obese individuals with BMI between 25 kg/m2 and 34.9 kg/m2

          -  stable body weight in previous 3 months

        Exclusion Criteria:

          -  Type 1 and Type 2 diabetes

          -  clinically significant cardiovascular abnormalities

          -  liver or pancreas disease

          -  major gastrointestinal surgeries

          -  are pregnant or lactating

          -  exhibit alcohol or drug dependence

          -  on drugs influencing appetite

          -  are following a diet or exercise regime designed for weight loss

          -  have a body mass greater than 350lb

          -  chronic use of antacids or bulk laxatives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raylene A. Reimer, PhD, RD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Kinesiology, Roger Jackson Centre for Health and Wellness Research</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 1N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2007</study_first_submitted>
  <study_first_submitted_qc>August 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2007</study_first_posted>
  <last_update_submitted>May 21, 2008</last_update_submitted>
  <last_update_submitted_qc>May 21, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2008</last_update_posted>
  <responsible_party>
    <name_title>Raylene Reimer, Associate Professor</name_title>
    <organization>University of Calgary</organization>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>weight loss</keyword>
  <keyword>satiety hormones</keyword>
  <keyword>body composition</keyword>
  <keyword>appetite ratings</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Body Weight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

